Who are Nelfinavir and Omeprazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nelfinavir-and-omeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nelfinavir and Omeprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nelfinavir and Omeprazole (Nelfinavir and Omeprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor + proton pump inhibitor combination. Area: Infectious Disease; Gastroenterology.

marketed HIV protease inhibitor + proton pump inhibitor combination HIV protease (nelfinavir); H+/K+-ATPase proton pump (omeprazole) Infectious Disease; Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Nelfinavir and Omeprazole (Nelfinavir and Omeprazole) — Pfizer. This is a combination of nelfinavir (an HIV protease inhibitor) and omeprazole (a proton pump inhibitor), which work through separate mechanisms to inhibit viral protease and reduce gastric acid respectively.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nelfinavir and Omeprazole TARGET	Nelfinavir and Omeprazole	Pfizer	marketed	HIV protease inhibitor + proton pump inhibitor combination	HIV protease (nelfinavir); H+/K+-ATPase proton pump (omeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor + proton pump inhibitor combination class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nelfinavir and Omeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/nelfinavir-and-omeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab